Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Pregnancy-Associated Hypertension, Gestational Hypertension, Preeclampsia, Eclampsia, HELLP Syndrome, Postpartum Hypertension, Stage 2 Hypertension
Interventions: Alabama Womb to Heart Solution (AW2H) Community Health Worker (CHW) Program, Usual postpartum care with self-measured blood pressure education and home blood pressure monitor; Behavioral · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years to 56 Years · Female only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: HIV Infections, HIV Seronegativity
Interventions: ALVAC(2)120(B,MN)GNP (vCP1452); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 13
States / cities: Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 8 more

Conditions: Health Impairment, Pain, Obesity
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Male only
Enrollment: 3,355 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1957 – 2011
U.S. locations: 2
States / cities: Cambridge, Massachusetts • Philadelphia, Pennsylvania

Conditions: Tetraplegia, Spinal Cord Injury
Interventions: Not listed
Lead sponsor: Craig Hospital; Other
Eligibility: Not listed
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: High Triglycerides
Interventions: NST-1024, Placebo; Drug · Other
Lead sponsor: NorthSea Therapeutics B.V.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 31
States / cities: Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more

Conditions: Hematologic Neoplasms
Interventions: donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: High-Risk Acute Myeloid Leukemia, Treatment-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: ALT-803; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Brain and Central Nervous System Tumors
Interventions: carboplatin, cisplatin, cyclophosphamide, etoposide, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Up to 10 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 29
States / cities: Phoenix, Arizona • Loma Linda, California • Long Beach, California + 21 more

Conditions: Prostate Cancer
Interventions: Erlotinib + Bevacizumab; Drug
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 16
States / cities: Alhambra, California • Bakersfield, California • Fullerton, California + 12 more

Conditions: Pulmonary Embolism
Interventions: Anticoagulation with heparin, EkoSonicTM Endovascular System; Drug · Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Newark, Delaware + 22 more

Conditions: Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis, AL Amyloidosis, Infiltrative Cardiomyopathy, Amyloid, ATTR Amyloidosis Wild Type
Interventions: Chest Wall Fat Tissue Collection; Procedure
Lead sponsor: Midwest Heart & Vascular Specialists; Other
Eligibility: 40 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Graft-versus-host Disease
Interventions: Cyclophosphamide, Abatacept, Bortezomib; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 14 Years to 100 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma, Recurrent Salivary Gland Cancer, Salivary Gland Acinic Cell Tumor, Salivary Gland Adenocarcinoma, Salivary Gland Poorly Differentiated Carcinoma, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer
Interventions: trastuzumab, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hypertension, Coronary Disease, Cerebrovascular Accident
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 55 Years and older
Enrollment: 37,939 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Houston, Texas

Conditions: Obesity
Interventions: Piperacillin/Tazobactam Standard Dose to High Dose; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma
Interventions: Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Leukapheresis, Lisocabtagene Maraleucel, Lumbar Puncture, Lymphodepletion Therapy, Multigated Acquisition Scan, Positron Emission Tomography, X-Ray Imaging, Biospecimen Collection; Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2043
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab Injection, Pembrolizumab Injection; Biological
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 97
States / cities: Chandler, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 86 more

Conditions: Cardiovascular Disease, Dyslipidemia, Inflammation
Interventions: Dietary Intervention; Other
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Adiposity, Insulin Sensitivity, Impaired Glucose Tolerance, Metabolic Disturbance
Interventions: Hypercaloric, High Fat Diet; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 20 Years to 45 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small Intestine Cancer
Interventions: DNA analysis, immunologic technique, pharmacological study, iodine I 131 monoclonal antibody 3F8, 131I-3F8; Genetic · Other · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension, Prehypertension, Insomnia
Interventions: Cognitive Behavioral Therapy, Healthy Sleep Habits; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Food Allergy in Infants
Interventions: Ready. Set. Food! Stage 1 Mix ins; Dietary Supplement
Lead sponsor: Prollergy dba Ready Set Food; Other
Eligibility: 2 Months to 5 Months
Enrollment: 1,110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Accidental Falls, Fall Due to Loss of Equilibrium, High Risk of Falls Due to Mobility Limitation, Diabetes, Arthritis, Cancer, Peripheral Arterial Disease, Parkinson's Disease, End Stage Renal Failure on Dialysis
Interventions: MBB AFO, Control; Device · Other
Lead sponsor: Bijan Najafi, PhD; Other
Eligibility: 65 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Essential Hypertension
Interventions: Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,071 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 84
States / cities: Gulf Shores, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 81 more

Search by objective public record fields.

Community Health Worker Support to Lower Blood Pressure After a Pregnancy With High Blood Pressure

Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults

High School Football and Adult Health

Follow up Study of Diaphragm Pacing for Patients With High Tetraplegia

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

Amyloidosis Incidence in High-Risk Cardiac Device Patients

Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Analyzing How Genetics May Affect Response to High Blood Pressure Medications

PK/PD of High Dose Pip/Tazo in Obese Patients

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

The Mediterranean Full-Fat Dairy Study

Metabolic Adaptations to High-fat Diet

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Online CBT-I for High Blood Pressure

Early Allergen System Experience

OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.